Gleason and colleagues developed an anti-CD16/CD19 BiKE and an anti-CD16/CD19/CD22 TriKE, and showed that they trigger NK cell activation through direct signaling of CD16 to secrete lytic granules and induce BL tumor death via a caspase-3 apoptosis pathway [94•]. This evidence concerns the gene CD19 and neoplasm.